Introduction: In order to address significant issues in cutaneous and transdermal drug administration, the goal of this study is to offer thorough insights into the procedures, formulation strategies, preparation techniques, and therapeutic uses of nanocrystals (NCs). Methods: A comprehensive examination of the literature was carried out, gathering and examining information from clinical trials, peer-reviewed publications, and pharmaceutical patents. Data about the synthesis, characterisation, and therapeutic use of NCs in transdermal and cutaneous drug delivery were assessed. Results: Drug loading, saturation solubility, and passive diffusion across the stratum corneum were all shown to be much improved by nanocrystals. Their larger surface area and nanoscale size boosted retention at the absorption site, promoted deeper skin penetration, and improved pharmacokinetics. The creation of stable, bioavailable NC formulations was accomplished by both top-down (such as milling and high-pressure homogenisation) and bottom-up (such as precipitation) approaches. Their therapeutic efficacy in treating ailments, including psoriasis, acne, and fungal infections, was backed by clinical and commercial data. Discussion: Notwithstanding compelling preclinical data, regulatory obstacles, formulation stability issues, scale-up constraints, and a dearth of standardised testing methods continue to restrict the clinical translation of NC-based skin formulations. The development of NC-based treatments might be greatly advanced by addressing these problems. Conclusion: A potent next-generation method for transdermal and cutaneous medication delivery is nanocrystal technology. Although further study is needed to address translational limitations, NCs have tremendous promise in treating a variety of skin ailments due to their capacity to improve solubility, penetration, and bioavailability.
Saikia et al. (Thu,) studied this question.